David Haen Articles

May 28, 2020 by David Haen

Now’s the Time to Buy These 3 Stocks

These drug developers will give your portfolio a boost.

May 26, 2020 by David Haen

Is Pfizer a Great Dividend Stock?

A strategic transaction this year will give investors two shots to earn dividends.

May 22, 2020 by David Haen

Should You Own This Sleeper Biotech Stock?

This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.

May 20, 2020 by David Haen

3 Top Pharma Stocks to Buy Right Now

Promising new drugs will drive these companies' stocks skyward.

May 18, 2020 by David Haen

Where Will Adaptimmune Be in 5 Years?

Pharma partners assist this cutting-edge cell-therapy company towards a successful future.

May 14, 2020 by David Haen

Will GenMark Diagnostics' Stock Keep Rising?

A coronavirus diagnostic test fuels revenue for 2020.

May 13, 2020 by David Haen

This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Third-quarter results from a COVID-19 trial could send this stock soaring.

May 8, 2020 by David Haen

Is There A Safer Way to Invest in a Coronavirus Vaccine?

Size may matter in the long run.

May 7, 2020 by David Haen

Is Axsome Therapeutics a Screaming Buy?

Two positive late-stage clinical trials may just be the beginning.

May 7, 2020 by David Haen

If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now

Not all IPO returns are equal.

May 4, 2020 by David Haen

Should You Buy Global Blood Therapeutics Before This Week's Earnings?

Next week investors will learn the progress of a new drug launch.

May 1, 2020 by David Haen

AstraZeneca Notches Win with Prostate Cancer Drug

New clinical trial results may lead to a label expansion this quarter for Lynparza, and huge revenue growth for the drug.

Apr 30, 2020 by David Haen

Did Merck Just Receive a Gift From the FDA?

A new, more convenient dosing schedule favors Keytruda.

Apr 29, 2020 by David Haen

Better Buy: Illumina vs. Adaptive Biotechnologies

One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.

Apr 28, 2020 by David Haen

Should You Buy Stock Now in This New Coronavirus Drug Developer?

This company's repurposed cancer drug might help patients with severe COVID-19.

Apr 27, 2020 by David Haen

Will Last Week's Biotech IPO Outperform a Recession?

This cancer drug developer will have smooth sailing ahead -- at least until it reports clinical trial results next year.

Apr 25, 2020 by David Haen

Myovant Squares Off with AbbVie On Endometriosis Treatment

With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.

Apr 23, 2020 by David Haen

Better Buy: AnaptysBio vs. Exelixis

Key clinical trial results this quarter will determine the better buy.

Apr 22, 2020 by David Haen

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

These biotechs just raised significant cash to advance promising drug pipelines.

Apr 21, 2020 by David Haen

Could CVS Health Be a Millionaire-Maker Stock?

Investors seek to capitalize on one of the broadest-reaching companies in healthcare.

David Haen

Recent Articles by David Haen